Aquinox Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch AQXP and buy or sell other stocks, ETFs, and their options commission-free!

About AQXP

Neurogene, Inc. is a clinical-stage biotechnology company, which engages in the development of product portfolio of genetic medicines for rare neurological diseases. The company was founded in May 2007 and is headquartered in New York, NY. 

CEO
Rachel L. McMinn, PhD
CEORachel L. McMinn, PhD
Employees
Employees
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
2018
Founded2018
Employees
Employees

AQXP Key Statistics

Market cap
322.23M
Market cap322.23M
Price-Earnings ratio
-4.39
Price-Earnings ratio-4.39
Dividend yield
Dividend yield
Average volume
163.95K
Average volume163.95K
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$37.27
52 Week high$37.27
52 Week low
$6.88
52 Week low$6.88

Stock Snapshot

The current Aquinox Pharmaceuticals(AQXP) stock price is $10.63, with a market capitalization of 322.23M. The stock trades at a price-to-earnings (P/E) ratio of -4.39.

On 2026-04-03, Aquinox Pharmaceuticals(AQXP) shares started trading at —, with intraday highs of — and lows of —.

Trading activity shows a volume of 0, compared to an average daily volume of 163.95K.

The stock's 52-week range extends from a low of $6.88 to a high of $37.27.

The stock's 52-week range extends from a low of $6.88 to a high of $37.27.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.